Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®

Ferring

Status: Withdrawn

Conditions: Growth Hormone Deficiency

Treatments: Drug: Somatropin

Study type: Observational

Funder types: Industry

Identifiers

NCT01731028

000091

Details and patient eligibility

About

The purpose of this study is to investigate the long-term treatment with Zomacton® for pituitary short stature in children with insufficient growth hormone production and/or short stature caused by Turner's syndrome.

Sex: All

Ages: 3 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• therapeutic need according to the approved specific products characteristics (SPC)

Exclusion criteria

• contraindication according to the SPC

Trial design

0 participants in 1 patient group

Somatropin

Description:

Children with growth hormone deficiency treated with somatropin as Zomacton® according to the marketing authorization

Treatment:

Drug: Somatropin